Neo-adjuvant versus Adjuvant chemotherapy in Upper Tract Urothelial Carcinoma: A feasibility phase II randomized clinical trial (“URANUS”)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514991-41-01

Acronym

2016-004017-27

Enrollment

190

Registered

2024-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

Brief summary

Proportion of UTUC patients randomized to neo or adjuvant chemotherapy that is actually able to start and finalize three courses of planned chemotherapy

Detailed description

1- 2 and 3-year Disease Free Survival (DFS), Overall Survival (OS) and Cancer-Specific Survival (CSS)

Interventions

DRUGGEMCITABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of UTUC patients randomized to neo or adjuvant chemotherapy that is actually able to start and finalize three courses of planned chemotherapy	—

Secondary

Measure	Time frame
1- 2 and 3-year Disease Free Survival (DFS), Overall Survival (OS) and Cancer-Specific Survival (CSS)	—

Countries

Netherlands, Norway, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026